Dissemination of VIM-2 producing Pseudomonas aeruginosa ST233 at tertiary care hospitals in Egypt

Mai Mahmoud Zafer1*, Mohamed Hamed Al-Agamy2,3, Hadir Ahmed El-Mahallawy4, Magdy Aly Amin5 and Seif El Din Ashour3

Abstract
Background: Pseudomonas aeruginosa is an important nosocomial pathogen, commonly causing infections in immunocompromised patients. The aim of this study was to examine the genetic relatedness of metallo-beta-lactamase (MBL) producing carbapenem resistant Pseudomonas aeruginosa clinical isolates collected from 2 tertiary hospitals in Cairo, Egypt using Multi Locus sequence typing (MLST).

Methods: Phenotypic and genotypic detection of metallo-beta-lactamase for forty eight non-duplicate carbapenem resistant P. aeruginosa isolates were carried out. DNA sequencing and MLST were done.

Results: The blaVIM-2 gene was highly prevalent (28/33 strains, 85%) among 33 MBL-positive P. aeruginosa isolates. MLST revealed eleven distinct Sequence Types (STs). A unique ST233 clone producing VIM-2 was documented by MLST in P. aeruginosa strains isolated from Cairo university hospitals. The high prevalence of VIM-2 producers was not due to the spread of a single clone.

Conclusions: The findings of the present study clearly demonstrate that clones of VIM-2 positive in our hospitals are different from those reported from European studies. Prevalence of VIM-2 producers of the same clone was detected from surgical specimens whereas oncology related specimens were showing diverse clones.

Keywords: Pseudomonas aeruginosa, Carbapenem resistance, blaVIM-2, ST233, Egypt

Background
Pseudomonas aeruginosa, an opportunistic pathogen, is an important cause of infection in patients with impaired immune systems [1]. P. aeruginosa is a prime example of a species that has continually evolved such that many strains are extensively drug resistant—i.e., resistant to all standard anti-pseudomonal antibiotics (carbapenems and aminoglycosides) and sensitive only to colistin [2]. Nowadays, intensive clinical use of carbapenems has caused the presence of carbapenem resistant P. aeruginosa populations [3] and an increase in carbapenem resistance by acquisition of different mechanisms, such as hyperproduction of chromosomal AmpC beta-lactamase, overexpression of efflux systems, alteration or lack of outer membrane proteins (such as porin OprD), and production of carbapenemases [4]. The advent of mobile MBL genes heralded a new chapter in resistance; class 1 integrons, the mobile genetic structures that carry MBL genes, also carry genes encoding determinants of resistance to aminoglycosides and other antibiotics, and thus confer extensive drug resistance [5]. MBL gene blaVIM-2 was first reported in P. aeruginosa in France in 2000, but the earliest recorded case was in Portugal in 1995 [6]. VIM-2 has emerged as a dominant MBL variant worldwide. MultiLocus sequence typing (MLST) has identified international clonal complexes (CCs) responsible for the dissemination of MBL-producing P. aeruginosa,

* Correspondence: mai_zafer@hotmail.com
1 Department of Microbiology and Immunology, Faculty of Pharmacy, Ahram Canadian University, 4th Industrial Zone, Banks Complex 6th of October, Giza, Egypt
Full list of author information is available at the end of the article

© 2015 Zafer et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
particularly in European countries [7], in Japan [8], Singapore, and Brazil. The aim of this study was to examine the genetic relatedness of MBL producing \textit{P. aeruginosa} strains isolated from two hospitals in Cairo, Egypt.

**Methods**

**Bacterial isolates**

Forty eight non-duplicate carbapenem resistant \textit{P. aeruginosa} isolates were obtained from clinical specimens submitted for bacteriological testing from hospitalized in-patients admitted to Kasr Al Aini Hospital (KAA) and National Cancer Institute (NCI), Cairo University, Egypt from January 2011 to January 2012. KAA School of Medicine and NCI are tertiary hospitals belonging to Cairo University, Egypt. The study was approved by the Ethics Committee of Cairo University and an informed consent was obtained from all patients receiving treatment and participating in the study.

**Isolate identification**

Initial identification and susceptibility testing was done using VITEK 2 (bioMerieux, Marcy l’Etoile, France) automated machine. Genotypic identification was carried out by PCR amplification and sequence determination of 16S rDNA previously described by Spilker et al. [9]. The identified strains were stored in glycerol broth cultures at - 70°C.

**Antimicrobial susceptibility testing**

Susceptibility testing was done by the disc diffusion method of the Clinical and Laboratory Standards Institute, [10] with discs from Oxoid (Oxoid Ltd., Basin Stoke, Hants, England). MICs were determined with E-test strips (bioMerieux, Marcy l’Etoile, France). \textit{P. aeruginosa} ATCC 27853 was used as a control throughout.

**Phenotypic detection of MBLs**

E-test MBL strips were in accordance with the manufacturer’s instructions to seek MBL production. A no less than eight-fold reduction in imipenem MIC in the presence of EDTA, or a phantom zone, was taken as a positive result.

**Detection of MBL-encoding genes and integrase genes**

\textit{bla}\textsubscript{VIM-2}, \textit{bla}\textsubscript{IMP-1}, \textit{bla}\textsubscript{SIM}, \textit{bla}\textsubscript{GIM}, \textit{bla}\textsubscript{SPM}, \textit{bla}\textsubscript{NDM-2} and \textit{intI1} were amplified for \textit{P. aeruginosa} isolates using primers listed in Table 1 according to the previous protocols [11-15]. Negative and positive controls were involved in all PCR experiments. Five microliters of reaction mix containing PCR product were analysed by electrophoresis in 0.8% (w/v) agarose (Fermentas, Lithuania).

**DNA sequencing**

Amplified products of \textit{bla}\textsubscript{VIM-2} were purified using a QIAquick PCR Purification Kit (Qiagen, Crawley, UK) and sequenced in both directions using the ABI Prism 3700 DNA Sequencer (Applied Biosystems, Foster City).

### Table 1 List of primers used in this study

| Primers | Sequence 5’-3’ | Use | Expected PCR product | Reference |
|---------|----------------|-----|----------------------|-----------|
| PA-SS-F | GGGGGATCTTCGAGACCTCA | Identification | 956 bp | Spilker et al. [9] |
| PA-SS-R | TCCCTAGAGTGGCCCAACCG | | | |
| \textit{bla}\textsubscript{IMP-1} | TGGCAAGTTATCTGTATTC | \textit{bla}\textsubscript{IMP-1} | 740 bp | Yan et al. [11] |
| | TTTAGCTGCTGTATTCATG | amplification | | |
| VIM-F1 | ATGTTCAACTTTTGTGAAGTATTATT | \textit{bla}\textsubscript{VIM-2} | 801 bp | Frasson et al. [12] |
| VIM-FK | ATGTAAAGTTATTAGTTATTAGTTC | amplification and sequencing | | |
| VIM1 | CTACTCCGGCAGCTGAGC | | | |
| VIM2 | CTACTCAACCGACTGAGCA | | | |
| \textit{bla}\textsubscript{NDM} | | | 984 bp | Kaase et al. [13] |
| Pre-NDM-A | CACCTCATGTTTGAATTCCGC | amplification | | |
| Pre-NDM-B | CTCTCTACATCGTAAAGGC | | | |
| \textit{bla}\textsubscript{SIM} | TACAGAATCCACCTTGGTGTTGAA | \textit{bla}\textsubscript{SIM} | 477 bp | Ellington et al. [12] |
| | AACTTCAAGTCGCCATGTA | amplification | | |
| \textit{bla}\textsubscript{SPM} | AAAATCTGGGTACGCAAAGC | \textit{bla}\textsubscript{SPM} | 271 bp | Ellington et al. [12] |
| | ACATTATCGCTGGAAACG | amplification | | |
| \textit{intI1} | | \textit{intI1} | 457 bp | Shibata et al. [15] |
| Int-1-F | GCA TCC TCGGTTTTCG | amplification and sequencing | | |
| Int-1-R | GGT GTC GCG GCG TTC GTG | | | |
CA). The types of β-lactamase genes were identified by comparison with the sequences in GenBank (http://blast.ncbi.nlm.nih.gov/Blast.cgi).

**Multi-locus sequence typing (MLST)**

PCR and sequencing of the recognized chromosomal markers (7 housekeeping genes) acsA, aroE, gusA, mutL, ndoD, ppsA, and trpE were done [16]. The nucleotide sequences of these genes were compared with the sequences submitted to the MLST database to determine the allelic numbers and sequence types.

The collection of MLST data on *P. aeruginosa* is available on http://pubmlst.org/paeruginosa/. MLST was performed for twenty isolates, representatives of the *bla*VIM-2 gene identified. All these isolates were imipenem resistant, MBL producing and VIM-2 positive. An isolate from each hospital was selected randomly for comparison.

**Results**

Of the 48 carbapenem resistant *P. aeruginosa* isolates, 33 (68.7%) were confirmed to be MBL producers. Of the 48 *P. aeruginosa* isolates, 21 isolates were from wound, 12 were from urine, 9 were from sputum, 4 were from blood and two were from ear swab; 16 (48.5%), 8 (24.2%), 6 (18.1%), 2 (6.1%) and 1 (3.0%) produced MBL, respectively.

Each of MBL positive strains and their MIC results are summarized in Table 2.

Of the 33 MBL isolates, MBL encoding genes *bla*VIM was identified in 28 (85%) isolates, *bla*NDM was identified in 2 (6.1%) isolates and *bla*IMP was identified in only one (3.0%) isolate. In this work MBL *bla*GIM, *bla*SIM, and *bla*SPM allele were not detected. Twenty nine (87.8%) of the MBL-producing isolates were positive for class 1 integron. All the VIM-2 producing isolates had the class 1 integron. All isolates were resistant to imipenem (MIC ≥ 8 μg/ml). Sequencing of intrinsic *bla*VIM confirmed that the nucleotide sequences obtained were identical to genes for VIM-2 for *P. aeruginosa*. Similarly, the nucleotide sequences of class 1 integron also coincided with the results predicted by the PCR analyses. Eleven distinct STs were identified. Results of STs analyzed are recorded in Table 2. Antibiotic susceptibility result for 33 MBL producing *P. aeruginosa* is given in Table 3.

**Discussion**

This study clearly demonstrates that carbapenem non-susceptible *P. aeruginosa* is present in Egypt in isolates of different origins mainly isolated from surgical wards with high prevalence of VIM-2 positivity in MBL producing *P. aeruginosa* isolates. The ability of MBL-producing *P. aeruginosa* to reach high level endemity in certain settings has, indeed, been established, [5] and in these cases, MBLs can outpace loss of oprD and up-regulated efflux pumps as leading factors causing reduced carbapenem susceptibility; distinct clones even unfolding their potential for causing outbreaks [17]. Our results revealed that 33 (68.7%) of 48 carbapenem resistant *P. aeruginosa* isolates produced MBL. This study demonstrated an increasing prevalence of MBL. Similarly high prevalence of MBL producing *P. aeruginosa* was detected in the Egyptian study where 82% were MBL producers [18]. In another Egyptian study 32.3% MBL producing *P. aeruginosa* was observed which is lower than our findings [19]. In the present study, VIM-2 was the most frequently detectable gene among the different MBL genes investigated; the percent of 85% among carbapenem-resistant MBL producing *P. aeruginosa* was detected. This finding was supported by results of previous studies demonstrating VIM-2 as the most dominant MBL implicated in imipenem resistant *P. aeruginosa* and confers the greatest clinical threat [20]. Worldwide, VIM-2 is the dominant MBL gene associated with nosocomial outbreaks due to MBL-producing *P. aeruginosa* [21]. Since MBL-producing isolates can cause serious infections that are difficult to treat, their presence in various hospitals in Egypt is of nationwide concern. The absence of new agents for the treatment of infections caused by these bacteria may lead to treatment failures with increased morbidity and mortality. A class 1 integron carries the integrase gene (int1), which encodes the site-specific recombinase responsible for cassette insertion. In our study class 1 integron was confirmed in 29 (87.8%) of MBL producing *P. aeruginosa*. This result is consistent with findings from Malaysia in which they suggested that the class 1 integron is the most abundant type of integron present among the clinical isolates of *P. aeruginosa* in Malaysia [22].

MDR *P. aeruginosa* isolates, resistant to almost all β-lactams, aminoglycosides and quinolones, often ascribed to epidemic clones (ST235 or ST111), have been detected in hospitals worldwide, mainly within ICU [23]. The increasing prevalence of MDR *P. aeruginosa* isolates is a global health problem, because of the limitation in clinical treatment options. All the VIM-producing isolates in this study belonged to international clones. In this study the results of MLST showed that VIM-2 type MBL carbapenem resistant *P. aeruginosa* specimens isolated from surgical wards of Kasr Al Aini hospital showed similarity in which ST233 which was a part of the internationally dominant clonal cluster CC233 was detected in 7/15 isolates indicating health care acquired transfer of *P. aeruginosa* could occur and should be prevented, an increased risk of cross-transmission and high antimicrobial pressure might have favoured clonal spread. Additionally, patients who have the potential to facilitate dissemination of MDR organisms between hospitals subsequently, might serve as important reservoirs and transmission sources, stressing the importance of hand hygiene compliance, and
patient precautions, whereas diversity in sequence types is shown from specimens isolated from NCI where 5 distinct sequence types were observed. This diversity could be due to previous empirical intake of antibiotics or misuse. ST 233 VIM-2 producing \textit{P.aeruginosa} was detected in one isolate imported from Ghana in a study done in Norway and Sweden in which the two international clonal complexes CC111 and CC235 associated with MBL-producing \textit{P. aeruginosa} isolates were dominant [24]. In previous studies from different Russian states, VIM-2 positive ST 235 was the predominant isolated type that has rapidly spread throughout Russia, Belarus and Kazakhstan via clonal dissemination. The authors were not able to prove the reason for spread of VIM-2 positive ST 235 but explained that inappropriate use of antibiotics and poor adherence to infection control practice could be among the reasons [25]. Although \textit{P.aeruginosa} clinical isolates are seldom typed and therefore under-reported, ST235 association with VIM-2 seems Europe centered, and has been reported in Belgium, Croatia, Serbia, and, more recently, Greece [26]. In other parts of Europe ST 111 were the major sequence type detected in MBL producing

| Isolate | Duration of episode in days | Sample | Hospital | VIM-2 | NDM-1 | IMP-1 | PM | Ptc | TZ | TZL | CI | AK | GM | IP | CT | Sequence type (ST) |
|---------|----------------------------|--------|---------|-------|-------|-------|----|-----|----|-----|----|----|----|----|----|------------------|
| 1       | 21                         | Wound  | KAA     | +     | -     | -     | ≥256 | 16  | ≥256 | ≥256 | 2   | 12  | 3   | ≥32 | ≥256           |
| 2       | 9                          | Blood  | KAA     | +     | -     | -     | 12   | 64  | 8    | 3    | ≥32 | 16  | ≥256| ≥256 | ≥256 |
| 3       | 36                         | Wound  | KAA     | +     | +     | -     | 8    | 64  | 64   | 24   | ≥32 | ≥256| 12  | ≥32 | ≥256 | 233 |
| 4       | 30                         | Wound  | KAA     | +     | -     | -     | 4    | 3   | 6    | 2    | ≥32 | ≥256| ≥256| ≥32 | ≥256 | 233 |
| 5       | 13                         | Wound  | KAA     | +     | -     | -     | 4    | 3   | 6    | 1.5  | ≥32 | ≥256| ≥256| ≥32 | ≥32  |
| 6       | 8                          | Wound  | KAA     | +     | +     | -     | 64   | ≥256| ≥256 | ≥256 | ≥232| ≥256| ≥256| ≥32 | ≥256 | 233 |
| 7       | 5                          | Wound  | KAA     | +     | -     | -     | 24   | ≥256| ≥256 | 192  | ≥32 | ≥256| 12  | ≥32 | ≥256 |
| 8       | 10                         | Wound  | KAA     | +     | -     | -     | 6    | 96  | 96   | 24   | 0.094| 4   | 2   | ≥32 | ≥256 |
| 9       | 10                         | Urine  | KAA     | +     | -     | -     | ≥256 | 3   | ≥256 | ≥256 | ≥32 | 12  | 3   | ≥32 | ≥256 | 303 |
| 10      | 9                          | Blood  | KAA     | +     | -     | -     | 2    | 4   | 1.5  | ≥32  | 2   | 2   | ≥32 | ≥256 |
| 11      | 75                         | Sputum | KAA     | +     | -     | -     | ≥256 | ≥256| ≥256 | ≥256 | ≥32 | ≥256| ≥32 | ≥32 | ≥256 |
| 12      | 4                          | Wound  | KAA     | +     | -     | -     | 6    | 24  | 8    | 16   | ≥32 | ≥256| ≥256| ≥32 | ≥32 | 198 |
| 13      | 30                         | Urine  | NCI     | +     | -     | -     | ≥256 | ≥256| ≥256 | ≥256 | ≥32 | ≥256| ≥256| ≥32 | ≥32 | 629 |
| 14      | 10                         | Sputum | NCI     | +     | -     | -     | ≥256 | ≥256| ≥256 | ≥256 | ≥32 | ≥32 | ≥32 | ≥32 | ≥32 | ≥32 |
| 15      | 30                         | Wound  | NCI     | +     | -     | -     | 16   | 990 | 15   | 303  | 59  | 233 |
| 16      | 46                         | Wound  | NCI     | +     | -     | -     | ≥256 | ≥256| 48   | 8    | ≥32 | 96  | ≥32 | ≥32 | ≥32 | 233 |
| 17      | 22                         | Sputum | NCI     | +     | -     | -     | 6    | 12  | 12   | 2    | ≥32 | 6   | ≥32 | ≥32 | ≥32 | 507 |
| 18      | 70                         | Sputum | NCI     | +     | -     | -     | ≥256 | 4   | ≥256 | ≥256 | ≥32 | 96  | ≥32 | ≥32 | ≥32 | 233 |
| 19      | 65                         | Sputum | NCI     | +     | -     | -     | ≥256 | ≥256| ≥256 | 96   | 0.094| 32  | 2   | ≥32 | ≥256 | 406 |
| 20      | 120                        | Sputum | NCI     | +     | -     | -     | 64   | 32  | 12   | 2    | ≥32 | 16  | ≥32 | ≥32 | ≥32 | 303 |
| 21      | 54                         | Wound  | KAA     | +     | -     | -     | 8    | 16  | 24   | 4    | ≥32 | 48  | ≥32 | ≥32 | ≥32 | 233 |
| 22      | 27                         | Wound  | KAA     | +     | -     | -     | 16   | ≥256| ≥256 | ≥256 | ≥32 | 128 | 32  | ≥32 | ≥32 | 274 |
| 23      | 7                          | Wound  | KAA     | +     | -     | -     | ≥256| ≥256| ≥256 | 256  | ≥32 | ≥256| ≥32 | ≥32 | ≥32 | 884 |
| 24      | 45                         | Urine  | KAA     | +     | -     | -     | 8    | 12  | ≥256 | 4    | 0.064| 8   | 32  | ≥32 | ≥32 | 738 |
| 25      | 150                        | Urine  | KAA     | +     | -     | -     | ≥256| ≥256| ≥256 | 128  | ≥32 | 48  | 32  | ≥32 | ≥32 | 274 |
| 26      | 75                         | Wound  | KAA     | +     | -     | -     | ≥256| ≥256| ≥256 | ≥256 | ≥32 | ≥256| ≥32 | ≥32 | ≥32 | 683 |
| 27      | 21                         | Urine  | KAA     | +     | -     | -     | 16   | ≥256| ≥256 | 32   | 0.064| 8   | 32  | ≥32 | ≥32 | 900 |
| 28      | 45                         | Urine  | KAA     | -     | -     | -     | 64   | ≥256| ≥256 | ≥256 | 0.064| 32  | 32  | ≥32 | ≥32 | 233 |
| 29      | 240                        | Urine  | KAA     | +     | -     | -     | 2    | 4   | 12   | 2    | 0.125| 4   | 2   | ≥32 | ≥32 | 233 |
| 30      | 180                        | Urine  | KAA     | +     | -     | -     | 2    | 4   | 8    | 1.5  | 0.125| 4   | 2   | ≥32 | ≥32 | 233 |
| 31      | 21                         | Wound  | KAA     | +     | -     | -     | 8    | 128 | 6    | 24   | 0.094| 6   | 2   | ≥32 | ≥32 | ≥32 |
| 32      | 30                         | Wound  | KAA     | -     | -     | -     | 12   | 32  | 2    | 8    | 0.064| 6   | 2   | ≥32 | ≥32 | ≥32 |
| 33      | 21                         | Ear swab| KAA    | +     | -     | -     | 6    | 6   | ≥256 | 8    | 3    | ≥32 | 128 | 16  | ≥32 | 233 |

PM = cefepime, Ptc = piperacillin/tazobactam, TZL = ceftazidime/clavulanic acid, TZ = ceftazidime, CI = ciprofloxacin, AK = amikacin, GM = gentamicin, IP = imipenem, CT = ceftotaxime.
| Isolate | Type of specimen | Antibiotic disk diffusion susceptibility test |
|---------|-----------------|---------------------------------------------|
|         |                 | Imipenem | Augmentin | Cefuroxime | Cefoperzone | Ceftazidime | Ciprofloxacin | Meropenem |
| 1       | Wound           | R        | R         | R          | R          | R           | R           | R         |
| 2       | Blood           | R        | R         | R          | R          | R           | R           | R         |
| 3       | Wound           | R        | R         | R          | R          | R           | R           | R         |
| 4       | Wound           | R        | R         | R          | R          | S           | R           | R         |
| 5       | Wound           | R        | R         | R          | R          | R           | S           | R         |
| 6       | Wound           | R        | R         | R          | R          | S           | R           | R         |
| 7       | Wound           | R        | R         | R          | R          | R           | R           | R         |
| 8       | Wound           | R        | R         | R          | R          | S           | R           | R         |
| 9       | Urine           | R        | R         | R          | R          | R           | R           | R         |
| 10      | Blood           | R        | R         | R          | R          | R           | R           | R         |
| 11      | Sputum          | I        | R         | R          | R          | R           | I           | R         |
| 12      | Wound           | R        | R         | R          | R          | R           | R           | R         |
| 13      | Urine           | R        | R         | R          | R          | R           | R           | R         |
| 14      | Sputum          | R        | R         | R          | R          | R           | I           | R         |
| 15      | Wound           | R        | R         | R          | R          | R           | R           | R         |
| 16      | Wound           | R        | R         | R          | R          | R           | R           | R         |
| 17      | Sputum          | R        | S         | R          | R          | S           | R           | R         |
| 18      | Sputum          | R        | R         | R          | S           | S           | R           | R         |
| 19      | Sputum          | R        | R         | R          | R          | R           | S           | R         |
| 20      | Sputum          | R        | R         | R          | R          | R           | R           | R         |
| 21      | Wound           | R        | R         | R          | R          | R           | R           | R         |
| 22      | Wound           | R        | R         | R          | R          | S           | R           | R         |
| 23      | Wound           | R        | R         | R          | R          | S           | R           | R         |
| 24      | Urine           | R        | R         | R          | R          | R           | R           | R         |
| 25      | Urine           | R        | R         | R          | R          | I           | R           | R         |
| 26      | Wound           | R        | R         | R          | R          | R           | I           | R         |
| 27      | Urine           | R        | R         | R          | R          | R           | R           | R         |
| 28      | Urine           | R        | R         | R          | R          | S           | R           | R         |
| 29      | Urine           | R        | R         | R          | R          | S           | R           | R         |
| 30      | Urine           | R        | R         | R          | R          | R           | R           | R         |
| 31      | Wound           | R        | R         | R          | R          | S           | R           | R         |
| 32      | Wound           | R        | R         | R          | R          | R           | R           | R         |
| 33      | Ear swab        | R        | R         | R          | R          | R           | R           | R         |
*P. aeruginosa* and ST 446 was detected but less widespread [27]. Thus it seems that different clones could be detected from different geographical areas.

**Conclusions**
The findings of the present study clearly demonstrate that clones of VIM-2 positive in our hospitals are different from those reported from European studies as none of our isolates revealed ST 235. Prevalence of VIM-2 producers of the same clone was detected from surgical specimens whereas oncology related specimens were showing diverse clones. Similar ST seems to be transmitted due to poor adherence to infection control policies which necessitate efforts for more strict abidance to infection control regulations. Different clones from different specialty hospitals in our study requiring further investigations to explain the relation of diversity of ST types to cause of resistance.

**Competing interests**
The authors declare that they have no competing interests.

**Authors’ contributions**
MZ carried out the phenotypic screening tests and drafted the manuscript. MHA carried out the molecular genetic studies, participated in sequence alignment. HAE participated in providing the clinical specimens and helped

| Isolate | Antibiotic disk diffusion susceptibility test |
|---------|---------------------------------------------|
|         | Amikacin | Sulperazone | Levofloxazin | Gentamicin | Norfloxacine | Tazocin | Ceftriaxone | Polymixin B |
| 1       | R        | R          | R            | R          | R            | R       | R          | S           |
| 2       | R        | I          | R            | R          | R            | R       | R          | S           |
| 3       | R        | R          | R            | R          | R            | R       | R          | S           |
| 4       | R        | R          | R            | R          | S            | R       | R          | S           |
| 5       | R        | R          | R            | R          | R            | R       | R          | S           |
| 6       | R        | R          | R            | R          | R            | S       | R          | S           |
| 7       | R        | R          | R            | R          | R            | R       | S           |
| 8       | R        | R          | R            | R          | R            | R       | S           |
| 9       | R        | R          | R            | R          | R            | R       | S           |
| 10      | S        | R          | R            | S          | R            | R       | R          | S           |
| 11      | R        | R          | R            | R          | R            | R       | I          | S           |
| 12      | R        | R          | R            | R          | R            | R       | R          | S           |
| 13      | S        | R          | R            | R          | R            | R       | R          | S           |
| 14      | S        | R          | R            | S          | R            | S       | R          | S           |
| 15      | S        | S          | R            | R          | R            | R       | S           |
| 16      | R        | R          | R            | R          | R            | R       | S           |
| 17      | R        | R          | R            | R          | R            | R       | S           |
| 18      | R        | R          | R            | R          | R            | R       | S           |
| 19      | S        | R          | R            | S          | R            | R       | R          | S           |
| 20      | R        | R          | R            | R          | R            | R       | S           |
| 21      | R        | R          | R            | R          | R            | R       | S           |
| 22      | R        | R          | S            | R          | R            | R       | S           |
| 23      | R        | R          | S            | R          | R            | R       | S           |
| 24      | R        | R          | R            | S          | R            | R       | S           |
| 25      | R        | R          | R            | R          | R            | R       | S           |
| 26      | R        | R          | R            | R          | R            | R       | S           |
| 27      | R        | R          | R            | R          | R            | R       | S           |
| 28      | R        | R          | S            | R          | S            | R       | S           |
| 29      | R        | R          | R            | R          | R            | R       | S           |
| 30      | R        | R          | R            | R          | R            | R       | S           |
| 31      | R        | R          | S            | R          | R            | R       | S           |
| 32      | R        | R          | R            | S          | R            | S       | R          | R           |
| 33      | S        | R          | R            | R          | R            | R       | S           |

Table 3 Resistance patterns of 33 *P. aeruginosa* MBL positive strains
to draft the manuscript. MA conceived of the study, and participated in its design and coordination. SA participated in the design of the study and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding the work through the research group project no. RGP-VPP-038.

Author details

1 Department of Microbiology and Immunology, Faculty of Pharmacy, Ahram Canadian University, 4th Industrial Zone, Banks Complex 6th of October, Giza, Egypt. 2 Department of Pharmaceutics and Microbiology, College of Pharmacy, King Saud University, 11451 Riyadh, Saudi Arabia. 3 Department of Microbiology and Immunology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. 4 Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt. 5 Department of Microbiology and Immunology, Faculty of pharmacy, Cairo University, El Ain, As Sayedah Zeinab, Cairo, Egypt.

Received: 27 September 2014 Accepted: 2 March 2015
Published online: 12 March 2015

References

1. Coggan KA, Wolfgang MC. Global regulatory pathways and cross-talk control. Pseudomonas aeruginosa environmental lifestyle and virulence phenotype. Curr Issues Mol Biol. 2012;14:47–70.
2. Cabot G, Ocampo-Sosa A, Dominguez MA, Gago JF, Juan C, Tubau F, et al. Spanish Network for Research in Infectious Diseases (REIPI): genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob Agents Chemother. 2012;56:3499–57.
3. Oikonomou O, Papoulopou M, Ikonomidou M. Investigation of carbapenem heteroresistance among different sequence types of Pseudomonas aeruginosa clinical isolates reveals further diversity. J Med Microbiol. 2011;60:1556–8.
4. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22:682–610.
5. Comaglia G, Giamarellou H, Rossolini GM. Metallo-β-lactamas: a last frontier for β-lactams? Lancet Infect Dis. 2011;11:381–93.
6. Cardoso O, Leitao R, Figueiredo A, Sousa JC, Duarte A, Peixe LV. Metallo-β-lactase-producer in clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother. 2008;59:45–74.
7. Kouda S, Obara M, Onodera M, Fujie Y, Sasaki M, Kohara T, et al. Increased prevalence and clonal dissemination of multidrug-resistant Pseudomonas aeruginosa with the blaIMP-1 gene cassette in Hiroshima. J Antimicrob Chemother. 2009;64:46–51.
8. Spiller T, Coenye T, Vandamme P, Liljum P. PCR-based assay for differentiation of Pseudomonas aeruginosa from other pseudomonas species recovered from cystic fibrosis patients. J Clin Microbiol. 2004;42:2074–9.
9. Clinical and Laboratory Standards Institute. Performance standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. M100-S24 and e100 CLSI. 2014.
10. Yan JJ, Hsueh PR, Chen K, Kwek T, Shu-Huei T, Hsiu-Mei W, et al. Metallo-β-Lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 Enzyme. Antimicrob Agents Chemother. 2001;45(8):2224–8.
11. Ellington MJ, Kistler J, Livermore DM, Woodford N. Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases. J Antimicrob Chemother. 2007;59:521–2.
12. Kaise M, Nordmann P, Wielchus TA, Gatermann SG, Bonnin RA, Pozel L. NDM-2 Carbapenemase in Acinetobacter baumannii from Egypt. J Antimicrob Chemother. 2011;10:1039–135.
13. Frasson I, Balsolo MA, Bartolini A, Cavallaro A, Richter SN, Palù G. Rapid detection of blaVIM1–37 and blaKPC1–2–12 alleles from clinical samples by multiplex PCR-based assays. Int J Antimicrob Agents. 2013;42:68–71.
14. Shibata N, Doi Y, Yamane K, Yagi T, Kurokawa H, ShibaYama K, et al. PCR typing of genetic determinants for Metallo-β-Lactamases and Integrase carried by Gram-Negative bacteria isolated in Japan, with focus on the class 3 Integron. J Clin Microbiol. 2003;41(12):5403–17.
15. Cunha B, Jonas D, Grundmann H, Pitt T, Dowson CG. Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. J Clin Microbiol. 2004;42:5644–9.
16. Tsakris A, Poulou A, Kristo I, Pittaras T, Spanakis N, Pourmaras S, et al. Large dissemination of VIM-2-metallo-(beta)-lactamase-producing Pseudomonas aeruginosa strains causing health-care-associated community-onset infections. J Clin Microbiol. 2009;47:3524–9.
17. Diab M, Farn N, El-Said M, El-Oabas E, El-Difrawy I, Saber M. Occurrence of VIM-2 Metallo-β-Lactamases in imipenem-resistant and susceptible Pseudomonas aeruginosa clinical isolates from Egypt. Afr J Microbiol Res. 2013;7(35):4465–72.
18. Mansour SA, Eldaly O, Fatani AJ, Mohamed ML, Ibrahim EM. Epidemiological characterization of P. aeruginosa isolates of intensive care units in Egypt and Saudi Arabia. East Mediterr Health J. 2013;19:1–8.
19. Walsh TR, Li H, Tolemen MA, Bennett PM, Jones RN. Complete sequence of p07–406, a 24,179-base-pair plasmid harboring the blaVIM-7 Metallo-β-Lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob Agents Chemother. 2008;52(9):3099–105.
20. Elias J, Schoen C, Heinez G, Valenza G, Gerharz E, Rednimmer H, et al. Nosocomial outbreak of VIM-2-metallo-β-lactamase-producing Pseudomonas aeruginosa associated with retrograde urography. Clin Microbiol Infect. 2010;16(9):1494–500.
21. Khosravi Y, Tay ST, Vadivelu J. Analysis of integrons and associated gene cassettes of metallo-β-lactamase-positive Pseudomonas aeruginosa in Malaysia. J Med Microbiol. 2011;60:988–94.
22. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev. 2011;35:736–55.
23. Samuelsen O, Tolemen MA, Sundsfjord A, Rjberg J, Leegaard TM, Walder M, et al. Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. Antimicrob Agents Chemother. 2010;54(1):346–52.
24. Edelman MV, Skoennova EN, Shevchenko OV, Drouza JW, Tapalski DV, Aziou IS, et al. Spread of extensively resistant VM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect Dis. 2015;13:867–76.
25. Koutsogiannou M, Drougka E, Liakopoulos A, Jelastopulu E, Petinaki E, Anastassiou ED, et al. Spread of multidrug-resistant Pseudomonas aeruginosa clones in a university hospital. J Clin Microbiol. 2015;53:665–8.
26. Van der Bij AK, Van der Zwan D, Peirano G, Severin JA, Pitout JJD, Westrenen MVW, et al. Metallo-β-lactamase-producing Pseudomonas aeruginosa in the Netherlands: the nationwide emergence of a single sequence type. Clin Microbiol Infect. 2012;18:E369–72.